National Center for Global Health and Medicine Report issue

Government Phase 2

Organization Overview

First Clinical Trial
2009
NCT01428986
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

National Center for Global Health and Medicine, Japan

Active Ingredients

Drugs in Phase 2 Trials (1)

pri-724 (1 trial)

Drugs in Other Trials (4)

darunavir (prezista) (1 trial)

maraviroc (selzentry) (1 trial)

raltegravir (isentress) (1 trial)

ritonavir (Norvir) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis C (Phase 2)

Liver Cirrhosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5